Management of Low-risk and Intermediate-risk Non–Muscle-invasive Bladder Carcinoma

2015 ◽  
Vol 29 (2) ◽  
pp. 219-225 ◽  
Author(s):  
Yme Weijers ◽  
Harm C. Arentsen ◽  
Tom J.H. Arends ◽  
J. Alfred Witjes
Keyword(s):  
Bladder Carcinoma ◽  
Low Risk ◽  
Intermediate Risk ◽  
Muscle Invasive

scholarly journals Recurrence and progression of non-muscle invasive bladder cancer following trans-urethral resection of bladder tumour with adjuvant intravesical chemo-immunotherapy

2020 ◽  
Vol 10 (3) ◽  
pp. 34-38
Author(s):  
Ashok Kumar Kunwar ◽  
Kabir Tiwari ◽  
Sanjesh Bhakta Shrestha ◽  
Srijana Thapa ◽  
Ashish Kumar Panthee ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Effective Treatment ◽  
Risk Group ◽  
Bladder Tumour ◽  
Low Risk ◽  
Invasive Bladder Cancer ◽  
Intermediate Risk ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

Background: Trans-urethral resection of bladder tumor is an essential diagnostic tool as well as effective treatment modality for non-muscle invasive bladder cancer. We aimed to evaluate the recurrence and progression of the non-muscle invasive bladder cancer in Nepalese patients. Methods: This was a retrospective study of 43 patients with non-muscle invasive bladder cancer, who underwent trans-urethral resection of bladder tumour followed by adjuvant intravesical instilla­tion of chemo or immunotherapy between January, 2013 to December, 2018. Patients were divided into low, intermediate and high-risk groups according to the clinical and pathological factors used by the European Organization for Research and Treatment of Cancer scoring system. Outcomes were calculated in terms of recurrence and progression in each group. Results: Out of 43 patients, 11 (25.58%) patients had low risk, 18 (41.86%) patients had intermediate risk and 14 (32.56%) patients had high risk of recurrence categories. No recurrence and progression of the disease noted in low risk group. In the intermediate risk group, out of 18 patients, 4 (22.2%) patients developed recurrence and 2 (11.1%) patients had progression of disease. In high risk group, out of 14 patients, 4 (26.8%) patients developed recurrence and 2 (14%) patients developed progres­sion of the disease. Conclusions: Even in a low volume centre of bladder cancer, effective treatment for non-muscle inva­sive bladder cancer with trans-urethral resection of bladder tumour followed by adjuvant intravesical chemo or immunotherapy can be given safely to reduce recurrence and progression of the disease.

The efficacy of EORTC risk tables in Japanese patients with non-muscle invasive bladder cancer.

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 331-331
Author(s):  
Satoru Muto ◽  
Takeshi Ieda ◽  
Syou-ichiro Sugiura ◽  
Akiko Nakajima ◽  
Akira Horiuchi ◽  
...  
Keyword(s):  
High Risk ◽  
Survival Time ◽  
Risk Group ◽  
Progression Free Survival ◽  
High Risk Group ◽  
Low Risk ◽  
Progression Rate ◽  
Intermediate Risk ◽  
Free Survival ◽  
Muscle Invasive

331 Background: To predict recurrence and progression of non-muscle invasive bladder cancer (NMIBC), EORTC risk tables are widely used worldwide. EORTC risk tables were, however, developed on the basis of individual data from 2,596 NMIBC patients included in seven special European Organization for Research and Treatment of Cancer trials. Therefore, it is not clear the efficacy of these risk tables in clinical practice, especially in Japan. I will report the recurrence and progression rate on the basis of EORTC risk tables in Japanese NMIBC patients. Methods: A retrospective analysis of 619 patients with NMIBC treated between January 1998 and 2012 was performed. Patients were divided into three groups on the basis of EORTC risk tables. We compared recurrence- and progression-free survival rates between groups. Recurrence- and progression-free survival was estimated using the Kaplan-Meier method. Results: We evaluated the clinical outcome of 1,032 TUR-Bt. The recurrence rate is 32.3% in low risk group (n=31), 44.5% in intermediate risk group (n=757), and 49.4% in high risk group (n=85). The median recurrence free survival time is 87 months in low risk group, 35 months in intermediate risk group, and 25 months in high risk group. Although there are significant differences in recurrence free survival time between low risk group and intermediate risk group (p=0.0351), there are no significant differences between intermediate risk group and high risk group (p=0.1871). On the other hand, the progression rate is 1.6% in low risk group (n=128), 5.8% in intermediate risk group (n=451), and 18.0% in high risk group (n=294). The median progression free survival time is 176 months in low risk group, 131 months in intermediate risk group, and 109 months in high risk group. There are significant differences in progression free survival time between low risk group and intermediate risk group (p=0.0138), and between intermediate risk group and high risk group (p=<0.0001). Conclusions: There is an urgent need to establish the standard of recurrence risk classification in Japan.

Cigarette Smoking Status at Diagnosis and Recurrence in Intermediate-risk Non–muscle-invasive Bladder Carcinoma

Urology ◽  
2013 ◽  
Vol 81 (2) ◽  
pp. 277-282 ◽  
Author(s):  
Vincenzo Serretta ◽  
Vincenzo Altieri ◽  
Giuseppe Morgia ◽  
Alessandra Di Lallo ◽  
Giuseppe Carrieri ◽  
...  
Keyword(s):  
Cigarette Smoking ◽  
Bladder Carcinoma ◽  
Smoking Status ◽  
Intermediate Risk ◽  
Muscle Invasive

1017 EXPECTANT MANAGEMENT FOR RECURRENT LOW RISK NON-MUSCLE-INVASIVE BLADDER CARCINOMA

2009 ◽  
Vol 8 (4) ◽  
pp. 375
Author(s):  
Canas V. Hernandez ◽  
M. Alvarez ◽  
La Peña E. De ◽  
N. Amaruch ◽  
M.D. Martin ◽  
...  
Keyword(s):  
Bladder Carcinoma ◽  
Expectant Management ◽  
Low Risk ◽  
Muscle Invasive

743: Methylation of the E-Cadherin and the TIMP-3 Genes are Positive Prognostic Markers for Patients with Non-Muscle Invasive Bladder Carcinoma

2004 ◽  
Vol 171 (4S) ◽  
pp. 197-197
Author(s):  
Martin G. Friedrich ◽  
Gangning Liang ◽  
Marieta I. Toma ◽  
Daniel J. Weisenberger ◽  
Jonathan C. Cheng ◽  
...  
Keyword(s):  
Bladder Carcinoma ◽  
Prognostic Markers ◽  
Muscle Invasive ◽  
E Cadherin

scholarly journals Perceptions of partial gland ablation for prostate cancer among men on active surveillance: a qualitative study

2021 ◽  
Vol 3 (1) ◽  
pp. e000068
Author(s):  
Sonia Hur ◽  
Michael Tzeng ◽  
Eliza Cricco-Lizza ◽  
Spyridon Basourakos ◽  
Miko Yu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Decision Making ◽  
Qualitative Study ◽  
Active Surveillance ◽  
Treatment Modality ◽  
Tertiary Care ◽  
Low Risk ◽  
Intermediate Risk ◽  
Perceptions And Attitudes ◽  
Partial Gland Ablation

ObjectivesPartial gland ablation (PGA) therapy is an emerging treatment modality that targets specific areas of biopsy-proven prostate cancer (PCa) to minimize treatment-related morbidity by sparing benign prostate. This qualitative study aims to explore and characterize perceptions and attitudes toward PGA in men with very-low-risk, low-risk, and favorable intermediate-risk PCa on active surveillance (AS).Design92 men diagnosed with very-low-risk, low-risk, and favorable intermediate-risk PCa on AS were invited to participate in semistructured telephone interviews on PGA.SettingSingle tertiary care center located in New York City.Participants20 men with very-low-risk, low-risk, and favorable intermediate-risk PCa on AS participated in the interviews.Main outcome measuresEmerging themes on perceptions and attitudes toward PGA were developed from transcripts inductively coded and analyzed under standardized methodology.ResultsFour themes were derived from 20 interviews that represent the primary considerations in treatment decision-making: (1) the feeling of psychological safety associated with low-risk disease; (2) preference for minimally invasive treatments; (3) the central role of the physician; (4) and the pursuit of treatment options that align with disease severity. Eleven men (55%) expressed interest in pursuing PGA only if their cancer were to progress, while nine men (45%) expressed interest at the current moment.ConclusionsAlthough an emerging treatment modality, patients were broadly accepting of PGA for PCa, with men primarily debating the risks versus benefits of proactively treating low-risk disease. Additional research on men’s preferences and attitudes toward PGA will further guide counseling and shared decision-making for PGA.

Sign in / Sign up

Export Citation Format

Share Document